| EN
We employ a market-oriented approach to R&D, addressing significant unmet medical needs, and focus our R&D efforts on innovative and high entry-barrier generic pharmaceuticals in oncology (including cell therapy), central nervous system disease and autoimmune disease therapeutic areas. Simcere's current product portfolio included over 40 brands, including 2 category I innovative drugs and 6 first-to-market drugs in China. Our existing product portfolio included over 10 products recommended in more than 40 clinical practice guidelines and pathways issued by government authorities or prestigious professional associations and over 20 products in the NRDL.

Oncology

  • Endostar®
  • Jepaso®
  • Jiebaili®
  • Sinofuan®
  • Enlength®

Central Nervous System

  • Sanbexin™
  • Bicun®
  • Ancozy®

Autoimmune

  • Iremod®
  • Orencia®
  • Yingtaiqing®

Cardiovascular & Anti-infection

  • OLMETEC PLUS®
  • Softan®
  • XINTA®
  • ZAILIKE®
  • YEQING®
  • ANQI®
  • Newanti®
  • ZAILIN®
  • ZAIKE®
  • 力宏®

Other Fields

  • Biqi®
  • Lowvo®
  • TB-PPD
  • KeChuanNing®
  • FANENG®
  • OUDIJIA®
  • DINGAN®

Search

[Disclaimer: Please use prescription drugs under the guidance of practicing doctors. Check only the instructions inside the packaging for valid product details.]